The prognosis of CMV retinitis among patients with AIDS in Serbia

被引:3
作者
Dujic, A. [2 ]
Jevtovic, Dj. [3 ]
Salemovic, D. [3 ]
Ranin, J. [3 ]
Brmbolic, B. [3 ]
Djurkovic-Djakovic, O. [1 ]
机构
[1] Univ Belgrade, Inst Med Res, Belgrade 11129, Serbia
[2] Clin Ctr Zvezdara, Dept Ophthalmol, Belgrade, Serbia
[3] Univ Belgrade, Sch Med, Clin Ctr Serbia, Inst Infect & Trop Dis, Belgrade 11129, Serbia
关键词
AIDS; CMV retinitis; survival;
D O I
10.1016/j.biopha.2007.12.011
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Cytomegalovirus (CMV) end-organ diseases, including CMV retinitis, are major opportunistic events in terminal AIDS patients. Methods: A retrospective study of 30 AIDS patients with CMV retinitis treated between 1997 and 2007 in Serbia was conducted to examine the prognosis and factors associated with survival. Results: Eighteen (60%) patients survived the mean follow-up period of 46.4 +/- 36 months. Patients' sex, mode of HIV transmission or previous AIDS diagnosis did not affect survival. Bilateral CMV retinitis predicted dissemination of CMV disease and poor prognosis (OR 7.8, 95% Cl 1.3-47.0, P = 0.012), but was not associated with blindness (P = 0.33). Among patients treated with HAART and CMV therapy the probability of surviving 10 years was 70%, while in those on CMV therapy alone, the median survival was 10 months (log rank P = 0.00). However, HAART itself was not sufficient to prevent blindness and the major predictor of blindness was a baseline CD4 cell count of less than 50/mu L (OR 6.8, 95% Cl 1.1-41.8, P = 0.03). After CMV disease, most patients suffered other opportunistic events regardless of HAART introduction. Conclusion: Even in the HAART era patients with advanced immunodeficiency and CMV retinitis may not escape from the high risk mortality group, while survivors commonly lose sight. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:443 / 447
页数:5
相关论文
共 17 条
[1]  
CARCELAIN G, 1999, AIDS REV, V1, P51
[2]  
Centers for Disease Control, 1993, MMWR Morb Mortal Wkly Rep, V41, P1
[3]   Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test [J].
Dodt, KK ;
Jacobsen, PH ;
Hofmann, B ;
Meyer, C ;
Kolmos, HJ ;
Skinhoj, P ;
Norrild, B ;
Mathiesen, L .
AIDS, 1997, 11 (03) :F21-F28
[4]   INCIDENCE AND NATURAL-HISTORY OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE [J].
GALLANT, JE ;
MOORE, RD ;
RICHMAN, DD ;
KERULY, J ;
CHAISSON, RE ;
BARTLETT, J ;
MCAVINUE, S ;
BRYSON, Y ;
COHEN, H ;
FISCHL, M ;
BOLIN, T ;
KESSLER, H ;
BURROUGH, Y ;
MILDVAN, D ;
FOX, A ;
RICHMAN, D ;
FREEMAN, B ;
SIMON, G ;
GRABOWY, KW ;
CHERNOFF, D ;
DUFF, P ;
THOMPSON, S ;
BARRETT, K ;
AWE, R ;
CHAPMAN, R ;
LEONARD, S ;
BAINES, L ;
TURNER, P ;
HAWKINS, M ;
MURRAY, H ;
BOWERS, J ;
LANE, C ;
TILSON, H ;
ANDREWS, E ;
SMILEY, L .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) :1223-1227
[5]  
Gea-Banacloche JC, 1999, AIDS, V13, pS25
[6]   Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy [J].
Goldberg, DE ;
Wang, H ;
Azen, SP ;
Freeman, WR .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2003, 87 (07) :853-855
[7]   Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy [J].
Jabs, DA ;
Holbrook, JT ;
Van Natta, ML ;
Clark, R ;
Jacobson, MA ;
Kempen, JH ;
Murphy, RL .
OPHTHALMOLOGY, 2005, 112 (05) :771-779
[8]   Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy - 1. Retinitis progression [J].
Jabs, DA ;
Van Natta, ML ;
Thorne, JE ;
Weinberg, DV ;
Meredith, TA ;
Kuppermann, BD ;
Sepkowitz, K ;
Li, HK .
OPHTHALMOLOGY, 2004, 111 (12) :2224-2231
[9]  
Jacobson M A, 1998, AIDS, V12 Suppl A, pS157
[10]   Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [J].
Jacobson, MA ;
Zegans, M ;
Pavan, PR ;
ODonnell, JJ ;
Sattler, F ;
Rao, N ;
Owens, S ;
Pollard, R .
LANCET, 1997, 349 (9063) :1443-1445